Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 trial of SelK2 in the treatment of Crohn's disease or other inflammatory indication

Trial Profile

A phase 2 trial of SelK2 in the treatment of Crohn's disease or other inflammatory indication

Planning
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs SELK 2 (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Apr 2018 New trial record
    • 18 Apr 2018 According to a Tetherex Pharmaceuticals media release, the company has successfully closed on a $50 million private placement of Series B preferred stock. Proceeds from the financing will be used to conduct this Phase 2 clinical trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top